# FluidAI Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fluidai-medical

- Industry: Healthcare IT
- Headquarters: Kitchener, Canada
- Website: www.fluidai.md
- Total disclosed funding: $18M
- Latest round: Series A (Oct 6, 2023)
- Investors on record: 13

## About

FluidAI Medical, based in Canada, specializes in innovative healthcare solutions that enhance postoperative patient management through advanced monitoring and analytics, promoting proactive healthcare and improved patient outcomes.FluidAI Medical, founded in 2014 in Kitchener, Canada, focuses on developing technologies for postoperative care. The company is led by CEO Youssef Helwa. Since its inception, FluidAI has participated in 13 funding deals, with its most recent deal occurring on February 12, 2025, where it secured CAD 2 million in GRANT funding from FedDev Ontario, bringing the total amount raised to CAD 20 million.FluidAI Medical's core offerings include Stream™ Care and Origin™, designed to enhance postoperative patient management through advanced monitoring and analytics. Stream™ Care provides continuous, personalized risk assessments for complications, while Origin™ is a sensing platform for abdominal surgery, offering real-time pH monitoring with laboratory-grade accuracy. Both products are targeted at healthcare facilities in Canada and are preparing for entry into the U.S. market pending regulatory approvals.FluidAI Medical's revenue model is based on B2B transactions with healthcare institutions, offering its products through subscription and direct sales agreements. Stream™ Care and Origin™ are key products aimed at improving clinical workflows and patient outcomes, with pricing structures reflecting the benefits of real-time monitoring. The Origin™ platform is cleared by Health Canada and SFDA, with FDA review pending, positioning the company for revenue expansion in the U.S. market.In February 2025, FluidAI Medical received CAD 2 million in grant funding from FedDev Ontario, which will be utilized to scale business operations, prepare for product commercialization, and expand into the global market. The company is focused on launching new products and aims to enter new markets, including the U.S., by securing the necessary regulatory approvals.

## Funding rounds

- Series A, Oct 6, 2023, $15M — SOSV, Graphene Ventures, Boutique Venture Partners, KYTO Technology & Life Science, ThresholdImpact, Cur8 Capital, Leva Capital, Juno Pharmaceuticals Corp.
- Series A, Jun 3, 2022 — SOSV
- Seed, Apr 21, 2021, $2.7M — SOSV, Graphene Ventures, NorthSpring Capital Partners, Boutique Venture Partners, NestGSV, Inc., ThresholdImpact
- Seed, Aug 1, 2020 — Boutique Venture Partners
- Seed, Jul 30, 2020 — SOSV, HAX
- Seed, Oct 9, 2019, $0.8M — Creative Destruction Lab, Sunhope Capital
- Seed, Oct 10, 2018 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- Creative Destruction Lab (https://capitalatlas.ai/funds/creative-destruction-lab) — Seed
- Sunhope Capital (https://capitalatlas.ai/funds/sunhope-capital) — Seed
- HAX — Seed
- Boutique Venture Partners (https://capitalatlas.ai/funds/boutique-venture-partners) — Seed, Series A
- Graphene Ventures (https://capitalatlas.ai/funds/graphene-ventures) — Seed, Series A
- NorthSpring Capital Partners — Seed
- NestGSV, Inc. — Seed
- ThresholdImpact (https://capitalatlas.ai/funds/thresholdimpact) — Seed, Series A
- KYTO Technology & Life Science (https://capitalatlas.ai/funds/kyto-technology-life-science) — Series A
- Cur8 Capital (https://capitalatlas.ai/funds/cur8-capital) — Series A
- Leva Capital (https://capitalatlas.ai/funds/leva-capital) — Series A
- Juno Pharmaceuticals Corp. — Series A